There are currently 852 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
NCT05113927
Recruiting
This is a multi-center, randomized, two-arm study designed to measure the effectiveness of the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard intraoperative margin assessment.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Baptist MD Anderson Cancer Center, Jacksonville, Florida +1 locations
Conditions: Breast Cancer
Register for Updates
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
All
Ages:
Between 22 years and 85 years
Trial Updated:
05/31/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Atrial Fibrillation
Register for Updates
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Cancer Specialist of North Florida, Jacksonville, Florida
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT02598349
Recruiting
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resectability. It may be argued that intensification of local and regional therapy might 1.) Increase the share of patients able to undergo curative surgery and 2.) Improve the local disease control interv... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida
Conditions: Pancreatic Cancer
Register for Updates
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
NCT06071845
Recruiting
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minim... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/30/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Esophageal Adenocarcinoma
Register for Updates
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
NCT05902962
Recruiting
A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University of Florida Health, Jacksonville, Florida
Conditions: Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
Register for Updates
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT00969111
Recruiting
The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate cancer returning.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: University of Florida Proton Therapy Institute, Jacksonville, Florida
Conditions: Prostate Cancer
Register for Updates
Registry Study for Radiation Therapy Outcomes
NCT01255748
Recruiting
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
Gender:
All
Ages:
All
Trial Updated:
05/30/2024
Locations: Ackerman Cancer Center, Jacksonville, Florida
Conditions: Neoplasms
Register for Updates
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
NCT06260267
Recruiting
To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Ferring Investigational Site, Jacksonville, Florida
Conditions: Ulcerative Colitis
Register for Updates
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709
Recruiting
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/30/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Register for Updates
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
NCT05573984
Recruiting
The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.
Gender:
All
Ages:
10 years and above
Trial Updated:
05/30/2024
Locations: University of Florida Health, Jacksonville, Florida
Conditions: Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
Register for Updates
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105
Recruiting
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: GIST
Register for Updates